1315 Capital Acquires Aluris Sciences
The carved-out business provides contract manufacturing for life sciences, diagnostics and combination drug products.
1315 Capital acquired Aluris Sciences, a contract manufacturing organization offering formulation, filling, kitting, lyophilization, assembly, packaging, and supply chain services to life sciences, diagnostics, and combination drug product customers. The business was carved out from Argonaut Manufacturing Services' Life Sciences and Diagnostics division and will operate independently with support from Philadelphia-based healthcare-focused investor 1315 Capital.
Aluris serves customers from pilot-stage programs through clinical, validation, and commercial production.
Deal facts
- Target
- Aluris Sciences
- Buyer
- 1315 Capital
- Sponsor
- 1315 Capital
- Seller
- Argonaut Manufacturing Services
- Deal type
- Platform
- Announced
- Wednesday, September 9, 2026
Sources
Written by Buyout Desk from the sources above. Spotted an error? Email corrections@buyoutdesk.com.